Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 24.1% in Chronic and 14.1% in Acute therapy segment.
Chronic category contributes to over 62.4% of our revenues as compared to 34.8% contribution to the IPM.
Eris is the second fastest growing company in Chronic therapy amongst the top 25 companies.
Source : IMS TSA MAT Mar 18(Compounded annual growth between Fiscal 2013 and 2018)
CAGR : Compounded annual growth rate between Fiscal 2013 and 2018
Our field force productivity of INR 3.6 Lac (YPM – Yield per Man per Month) is industry leading and we are amongst the most productive companies in the Industry.
Our product portfolio is primarily focused on therapeutic areas which are treated by super specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, and Gastroenterologists. Super specialists and specialists contribute to 92.6% of our total prescriptions as compared to 61.6% for the IPM. We have an average prescriber base of 80,267 doctors for Fiscal 2018 as per IMS medical audit.
Super specialist and specialist doctor prescription contribution
Source IMS Medical Audit MAT March,2018
Eris has a portfolio of high growth prescription products. We derive majority of our prescriptions from molecules which are in growth phase of the product lifecycle.
|Lifecycle of Pharmaceutical Molecules||Eris Lifesciences||IPM|
Source: SMSRC, based on data for MAT February 2017
|Doctor Specialty||Rank FY 2018|
Source IMS Medical Audit MAT Mar 2018, Prescription rank within Eris represented market